BG64367B1 - Метод за получаване на воден фармацевтичен състав - Google Patents

Метод за получаване на воден фармацевтичен състав Download PDF

Info

Publication number: BG64367B1
Authority: BG; Bulgaria
Prior art keywords: weight; active substance; liposomes; aqueous; phase
Prior art date: 1997-02-20

Application number

BG103739A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103739A (en

Inventor

Giovanni Cavallo

Leonardo Marchitto

Original Assignee

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-20

Filing date

1999-09-16

Publication date

2004-12-30

1999-09-16 Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

2000-06-30 Publication of BG103739A publication Critical patent/BG103739A/xx

2004-12-30 Publication of BG64367B1 publication Critical patent/BG64367B1/bg

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
238000004519 manufacturing process Methods 0.000 title abstract 2
239000002502 liposome Substances 0.000 claims abstract description 29
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims description 31
239000013543 active substance Substances 0.000 claims description 19
238000001125 extrusion Methods 0.000 claims description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
239000000725 suspension Substances 0.000 claims description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
230000008014 freezing Effects 0.000 claims description 11
238000007710 freezing Methods 0.000 claims description 11
239000012071 phase Substances 0.000 claims description 11
238000010438 heat treatment Methods 0.000 claims description 7
150000002632 lipids Chemical class 0.000 claims description 7
239000011780 sodium chloride Substances 0.000 claims description 7
239000007789 gas Substances 0.000 claims description 6
239000001307 helium Substances 0.000 claims description 6
229910052734 helium Inorganic materials 0.000 claims description 6
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
239000012528 membrane Substances 0.000 claims description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
239000006185 dispersion Substances 0.000 claims description 4
239000008346 aqueous phase Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
239000011148 porous material Substances 0.000 claims description 3
229910052786 argon Inorganic materials 0.000 claims description 2
238000001914 filtration Methods 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 description 24
239000000203 mixture Substances 0.000 description 15
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 13
229940079593 drug Drugs 0.000 description 13
239000003814 drug Substances 0.000 description 13
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 13
229960003987 melatonin Drugs 0.000 description 13
239000000243 solution Substances 0.000 description 11
229930105110 Cyclosporin A Natural products 0.000 description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
108010036949 Cyclosporine Proteins 0.000 description 7
229960001265 ciclosporin Drugs 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 7
229920000515 polycarbonate Polymers 0.000 description 5
239000004417 polycarbonate Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
101710150402 Mastin Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
-1 diglycerides Chemical class 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002327 glycerophospholipids Chemical class 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
229960003538 lonidamine Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG103739A 1997-02-20 1999-09-16 Метод за получаване на воден фармацевтичен състав BG64367B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT97MI000363A IT1289939B1 (it)	1997-02-20	1997-02-20	Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua

Publications (2)

Publication Number	Publication Date
BG103739A BG103739A (en)	2000-06-30
BG64367B1 true BG64367B1 (bg)	2004-12-30

Family

ID=11376099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103739A BG64367B1 (bg)	1997-02-20	1999-09-16	Метод за получаване на воден фармацевтичен състав

Country Status (26)

Country	Link
US (1)	US6337087B1 (fr)
EP (1)	EP0973505B1 (fr)
JP (1)	JP4299369B2 (fr)
KR (1)	KR100515249B1 (fr)
CN (1)	CN1135969C (fr)
AR (1)	AR011682A1 (fr)
AT (1)	ATE257374T1 (fr)
AU (1)	AU740619B2 (fr)
BG (1)	BG64367B1 (fr)
CA (1)	CA2285985C (fr)
CZ (1)	CZ296700B6 (fr)
DE (1)	DE69821001T2 (fr)
DK (1)	DK0973505T3 (fr)
EA (1)	EA002281B1 (fr)
ES (1)	ES2213894T3 (fr)
GE (1)	GEP20022751B (fr)
HU (1)	HU225594B1 (fr)
IL (2)	IL131354A0 (fr)
IT (1)	IT1289939B1 (fr)
PL (1)	PL190987B1 (fr)
PT (1)	PT973505E (fr)
SK (1)	SK282905B6 (fr)
TR (1)	TR199901987T2 (fr)
UA (1)	UA63939C2 (fr)
WO (1)	WO1998036735A1 (fr)
ZA (1)	ZA981354B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9804192D0 (sv) *	1998-12-03	1998-12-03	Scotia Lipidteknik Ab	New formulation
US6075045A (en) *	1999-04-28	2000-06-13	Ajinomoto Co., Inc.	Method of treating paralysis of the extremities caused by cerebral infarction
JP4894119B2 (ja) *	2001-09-26	2012-03-14	日油株式会社	脂肪酸含有リポソーム分散液
US20040115226A1 (en) *	2002-12-12	2004-06-17	Wenji Li	Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
EP1610778A4 (fr) *	2003-01-17	2006-05-31	Threshold Pharmaceuticals Inc	Traitement de l'hypertrophie prostatique benigne
WO2005105040A2 (fr) *	2004-04-26	2005-11-10	Micelle Products, Inc.	Preparation hydrosoluble de vitamines liposolubles, agents pharmaceutiques et leurs applications
US8999292B2 (en)	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
WO2020123407A1 (fr) *	2018-12-11	2020-06-18	Disruption Labs Inc.	Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
CN111759807B (zh) *	2019-04-01	2021-06-01	上海谷森医药有限公司	一种环孢素脂质体及其制备方法
AU2019441740B2 (en)	2019-04-18	2025-12-18	Tracery Ophthalmics Inc.	Detection, prediction, and classification for ocular disease
EP3990433B1 (fr)	2019-06-25	2026-05-20	Translatum Medicus Inc.	Procédés de fabrication d'acide 2-((1-benzyl-1h-indazol-3-yl)méthoxy)-2-méthylpropanoïque et de ses dérivés

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4038075C1 (en) *	1990-11-29	1992-03-19	B. Braun Melsungen Ag, 3508 Melsungen, De	Encapsulating solid or liq. lipophilic agents - comprises mixing hydration medium with phospholipid increasing temp. to above soln. phase change temp. and adding remaining medium
EP0578629A1 (fr) *	1992-07-09	1994-01-12	ÖSKO, Österreichische Säurebau- und Korrosionsschutz Gesellschaft mbH	Procédé de purification d'un flux de gaz de fumée à l'aide d'un liquide laveur
DE4430593A1 (de) *	1994-08-20	1996-02-22	Max Delbrueck Centrum	Liposomal verkapseltes Taxol, seine Herstellung und seine Verwendung
WO1996040064A1 (fr) *	1995-06-07	1996-12-19	Nexstar Pharmaceuticals, Inc.	Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1264668C (fr) *	1984-06-20	1990-01-23		Techniques d'extrusion pour la production de liposomes
IT1254995B (it) *	1992-06-24	1995-10-11		Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
FR2716110B1 (fr) *	1994-02-16	1996-04-05	Roussel Uclaf	Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.

1997
- 1997-02-20 IT IT97MI000363A patent/IT1289939B1/it active IP Right Grant
1998
- 1998-02-12 AT AT98909460T patent/ATE257374T1/de active
- 1998-02-12 AU AU63987/98A patent/AU740619B2/en not_active Ceased
- 1998-02-12 HU HU0000910A patent/HU225594B1/hu not_active IP Right Cessation
- 1998-02-12 EP EP98909460A patent/EP0973505B1/fr not_active Expired - Lifetime
- 1998-02-12 EA EA199900750A patent/EA002281B1/ru not_active IP Right Cessation
- 1998-02-12 CA CA002285985A patent/CA2285985C/fr not_active Expired - Fee Related
- 1998-02-12 ES ES98909460T patent/ES2213894T3/es not_active Expired - Lifetime
- 1998-02-12 SK SK1111-99A patent/SK282905B6/sk not_active IP Right Cessation
- 1998-02-12 CN CNB98802733XA patent/CN1135969C/zh not_active Expired - Fee Related
- 1998-02-12 KR KR10-1999-7007539A patent/KR100515249B1/ko not_active Expired - Fee Related
- 1998-02-12 TR TR1999/01987T patent/TR199901987T2/xx unknown
- 1998-02-12 WO PCT/EP1998/000816 patent/WO1998036735A1/fr not_active Ceased
- 1998-02-12 DE DE69821001T patent/DE69821001T2/de not_active Expired - Lifetime
- 1998-02-12 DK DK98909460T patent/DK0973505T3/da active
- 1998-02-12 GE GEAP19984992A patent/GEP20022751B/en unknown
- 1998-02-12 IL IL13135498A patent/IL131354A0/xx unknown
- 1998-02-12 US US09/367,699 patent/US6337087B1/en not_active Expired - Lifetime
- 1998-02-12 CZ CZ0292699A patent/CZ296700B6/cs not_active IP Right Cessation
- 1998-02-12 PL PL335208A patent/PL190987B1/pl unknown
- 1998-02-12 JP JP53622798A patent/JP4299369B2/ja not_active Expired - Fee Related
- 1998-02-12 PT PT98909460T patent/PT973505E/pt unknown
- 1998-02-18 ZA ZA981354A patent/ZA981354B/xx unknown
- 1998-02-20 AR ARP980100755A patent/AR011682A1/es active IP Right Grant
- 1998-12-02 UA UA99095151A patent/UA63939C2/uk unknown
1999
- 1999-08-11 IL IL131354A patent/IL131354A/en not_active IP Right Cessation
- 1999-09-16 BG BG103739A patent/BG64367B1/bg unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4038075C1 (en) *	1990-11-29	1992-03-19	B. Braun Melsungen Ag, 3508 Melsungen, De	Encapsulating solid or liq. lipophilic agents - comprises mixing hydration medium with phospholipid increasing temp. to above soln. phase change temp. and adding remaining medium
EP0578629A1 (fr) *	1992-07-09	1994-01-12	ÖSKO, Österreichische Säurebau- und Korrosionsschutz Gesellschaft mbH	Procédé de purification d'un flux de gaz de fumée à l'aide d'un liquide laveur
DE4430593A1 (de) *	1994-08-20	1996-02-22	Max Delbrueck Centrum	Liposomal verkapseltes Taxol, seine Herstellung und seine Verwendung
WO1996040064A1 (fr) *	1995-06-07	1996-12-19	Nexstar Pharmaceuticals, Inc.	Formulations liposomales contenant de la cyclosporine, utilisees comme agents immunosuppresseurs et pour le traitement de multiples cas pharmacoresistants

Also Published As

Publication number	Publication date
CZ296700B6 (cs)	2006-05-17
AU740619B2 (en)	2001-11-08
EA199900750A1 (ru)	2000-04-24
IL131354A (en)	2010-06-30
CA2285985A1 (fr)	1998-08-27
ATE257374T1 (de)	2004-01-15
CN1255057A (zh)	2000-05-31
PL190987B1 (pl)	2006-02-28
PT973505E (pt)	2004-05-31
EA002281B1 (ru)	2002-02-28
AR011682A1 (es)	2000-08-30
WO1998036735A1 (fr)	1998-08-27
JP4299369B2 (ja)	2009-07-22
HUP0000910A3 (en)	2000-11-28
TR199901987T2 (xx)	1999-11-22
CA2285985C (fr)	2008-01-29
US6337087B1 (en)	2002-01-08
ZA981354B (en)	1998-08-17
DE69821001D1 (de)	2004-02-12
SK111199A3 (en)	2000-06-12
EP0973505A1 (fr)	2000-01-26
SK282905B6 (sk)	2003-01-09
AU6398798A (en)	1998-09-09
HU225594B1 (en)	2007-05-02
CN1135969C (zh)	2004-01-28
HUP0000910A2 (hu)	2000-10-28
PL335208A1 (en)	2000-04-10
DK0973505T3 (da)	2004-05-03
GEP20022751B (en)	2002-08-26
DE69821001T2 (de)	2004-11-11
JP2001519775A (ja)	2001-10-23
BG103739A (en)	2000-06-30
CZ292699A3 (cs)	2000-01-12
KR100515249B1 (ko)	2005-09-16
ITMI970363A1 (it)	1998-08-20
KR20000075480A (ko)	2000-12-15
ES2213894T3 (es)	2004-09-01
IT1289939B1 (it)	1998-10-19
EP0973505B1 (fr)	2004-01-07
UA63939C2 (uk)	2004-02-16
IL131354A0 (en)	2001-01-28

Publication	Publication Date	Title
US5616334A (en)	1997-04-01	Low toxicity drug-lipid systems
US6406713B1 (en)	2002-06-18	Methods of preparing low-toxicity drug-lipid complexes
US4761288A (en)	1988-08-02	Multiphase liposomal drug delivery system
RU2216315C2 (ru)	2003-11-20	Способ получения липосом
US4897269A (en)	1990-01-30	Administration of drugs with multiphase liposomal delivery system
JP2911814B2 (ja)	1999-06-23	リポソーム性の水中分散する経口投与可能な固体乾燥治療用処方の製造方法
EP0177223B1 (fr)	1990-02-28	Composition pharmaceutique à multiphases
JPS6339810A (ja)	1988-02-20	リポソ−ムの製造法
EP0282405B2 (fr)	1998-07-22	Systèmes médicament-lipide à basse toxicité
CA2162341A1 (fr)	1996-05-10	Vehicules pharmaceutiques
JP2574309B2 (ja)	1997-01-22	一様な二重層化されたリポソームの製造法
BG64580B1 (bg)	2005-08-31	Фармацевтичен състав, съдържащ лиофилизирани липозоми, включващи трудно разтворимо във вода активно вещество и метод за получаването на този състав
HK1007495B (en)	1999-04-16	Low toxicity drug-lipid systems
US5173219A (en)	1992-12-22	Uniform spherical multilamellar liposomes of defined and adjustable size distribution
EP0973505B1 (fr)	2004-01-07	Composition pharmaceutique aqueuse comprenant un principe actif essentiellement insoluble dans l'eau
JPH0824840B2 (ja)	1996-03-13	サブミクロン大リポソームの形態の両親媒性脂質の分散性コロイド系の調製方法
JP3399009B2 (ja)	2003-04-21	リポソームの製造方法
US20020119170A1 (en)	2002-08-29	Low toxicity drug-lipid systems
MXPA99007683A (en)	2000-06-01	Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water